The innovative genXone company, operating in the biotech industry, has signed a letter of intent with gMendel® ApS, in which the companies have declared their willingness to cooperate in the future in the field of diagnosis of genetic disorders. The aim of cooperation is to lead to the modernization of the research process and increasing their availability.
Danish biotechnology company gMendel® aims to transform the diagnosis and treatment of genetic disorders through the power of genomics, machine learning and blockchain. The assumption of the research carried out by gMendel® is to provide the end recipient with the most precise diagnosis result in the shortest possible time.
As part of cooperation with genXone, the companies will use each other’s technologies and know-how, as well as jointly adapt diagnostic tools to the market needs. These activities are aimed to optimize the process of diagnosing genetic disorders.
– The gMendel® and genXone teams share not only a strong technological base and extensive experience, but most of all – the will to revolutionize the approach to genetic research. The cooperation we have started confirms our announcements about expanding the company’s operations outside the country, and fulfills our dreams of greater availability of tests and the early possible diagnosis of patients. Therefore, we see a huge potential for the development of this cooperation – said Michał Kaszuba, CEO of genXone.

-At gMendel®, we are excited to start the collaboration with genXone, the largest provider of next generation sequencing using nanopore technology in Poland. Through this collaboration we look forward to expanding the delivery capability of our proprietary technology in Poland and beyond, in line with our ambition to ultimately transform patient lives and offer breakthrough solutions to national healthcare systems”, said Chris Kyriakidis, Co-founder of gMendel® – said Chris Kyriakidis, CEO and Co-founder of gMendel®.

Currently available solutions in the field of genetic disorders research have many limitations, including due to their complexity, time-consumption, and high costs related to the performance of analyzes. The signed letter of intent aims to solve the problems faced personally by the founders of gMendel® in the past. It was the personal experiences related to the diseases of their relatives, in which diagnosis was possible only thanks to DNA sequencing. It inspired them to start a company.
In 2020, they concluded that they wanted to turn this complicated medical process into a routine clinical practice.
genXone is a company open to modern technologies and innovative approach to specialized research. Cooperation with leaders in the treatment of genetic disorders proves the high competence of the team, which is clearly noticeable even in a background of increasing competition. The company’s experience has determined, among others, about its election last year to the state program for monitoring genetic variability of the SARS-CoV-2 virus.
The genXone and gMendel® companies do not rule out extending work in the diagnosis of genetic disorders. They are also considering cooperation in the future in the implementation of Danish technology on the Polish market.